Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Share Price Crosses Above Two Hundred Day Moving Average – Should You Sell?

Shares of Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) crossed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $9.65 and traded as high as $10.0699. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $9.9699, with a volume of 73,749 shares trading hands.

Wall Street Analyst Weigh In

SGIOY has been the topic of several analyst reports. Jefferies Financial Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 14th. Zacks Research upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 15th. Three research analysts have rated the stock with a Strong Buy rating. According to data from MarketBeat, the stock currently has an average rating of “Strong Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

The company has a fifty day moving average of $9.22 and a 200 day moving average of $9.65. The firm has a market capitalization of $16.97 billion, a P/E ratio of 11.08, a PEG ratio of 3.41 and a beta of 0.10. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.14 and a quick ratio of 1.00.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last released its earnings results on Thursday, October 29th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.05). The firm had revenue of $1.18 billion for the quarter, compared to analyst estimates of $1.11 billion. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 37.95% and a return on equity of 14.32%. Sell-side analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.83 earnings per share for the current year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japanese pharmaceutical company headquartered in Osaka, Japan. Founded in 1878, the company researches, develops, manufactures and markets prescription medicines, with a longstanding focus on infectious diseases and specialty therapies.

Its products and development programs have included Xofluza (baloxavir marboxil), an oral treatment for influenza; Fetroja (cefiderocol), an antibiotic for certain difficult-to-treat Gram-negative bacterial infections; and medicines for central nervous system disorders, pain and other therapeutic areas.